Best Life Sciences Platforms and Tools Companies in Beijing, China
The 56 best Life Sciences Platforms and Tools companies in Beijing, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Geneplus Technology.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Beijing
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Absea Manufactures antibodies | — | — | Unfunded | Wei Zhang CEO & MD | — | — | — | — |
| 2 | Aoxing Life Science and Technology Manufactures laboratory equiment | — | — | Public | He Guoqiang Founder & CEO | 1,838 | — | — | — |
| 3 | ASPEC Technologies In-situ ionization mass spectrometry analysis technology | — | — | Funding Raised | Charles Liu CEO & President | — | — | — | — |
| 4 | Beijing Bohui Innovation Technology Instruments systems for biomedical and research application | — | — | Public | Lu Xinqun CEO | 1,773 | — | — | — |
| 5 | beijing chieftain control engineering technology Beijing Chieftain Control Engineering Technology manufactures and produces integrated solutions of… | — | — | Public | — | 1,665 | — | — | — |
| 6 | Beijing Dongsheng Innovation Biotechnology Provider of services for research and development for life-science industry | — | — | Funding Raised | Zhang CEO | — | — | — | — |
| 7 | Beijing Genenode Biotech Provider of services and products in genomics and molecular biology | — | — | Unfunded | Changyuan Zhang CEO | — | — | — | — |
| 8 | Beijing Health-Biotech Group Provider of diversified product and services | — | — | Funding Raised | Zhihai HAN CEO | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Beijing
#1
Series B · Beijing, Beijing · founded 2017 · 65 employees$35.4Mraised▾
Provider of engineered cell lines for the discovery of oncology drugs. The service portfolio of the company includes Engineered custom cell line development, Cell-based assay, and drug screening, Antibody-drug discovery, and Cancer cell panel profiling and Biomarker discovery.
- Dec 2025Series B$35.4M
- Nov 2021Series A—
#2
Series C · Beijing, Beijing · founded 2015 · 50 employees$50.6Mraised▾
Developer of microbial separation and cultivation technologies. It has developed Eco-screening TM technology, fungal high-density solid fermentation technology foroxygen, H2O, pH value, carbon, & nitrogen source, and microfilm coating technology on the surface of seeds to stop the damage of microorganisms. It has applications in biological agriculture, human microbiome research biomedicine, and gene discovery.
- Jul 2024Series C$41.3M
- Feb 2020Series B—
- Jun 2018Seed$9.3M
#3
Series B · Beijing, Beijing · founded 2016 · 120 employees$133Mraised▾
Developer of synthetic biology and biomaterial. The company has microbial manufacturing technology that helps in developing bio-based products for a broad range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics, and more
- Feb 2023Conventional Debt$73.3M
- Feb 2023Series B$58.6M
- Jan 2022Series B—
- Aug 2021Series B$66.4M
#4
Series B · Haidian, Beijing · founded 2015$23.2Mraised▾
Beijing Xinyi Biotechnology is manufacturing micro-droplet digital PCR and in vitro diagnostic reagents. Products include drop maker sample preparation, chip reader, PCR universal amplification reagent, genetic testing kit (for scientific research only), micro-droplet detection oil, nucleic acid extraction reagent (magnetic beads method), etc.
- Feb 2024Series B—
- Jan 2021Series B$23.2M
- Sep 2018Seed—
#5
Series C · Beijing, Beijing · founded 2015$220.2Mraised▾
Developer of next-generation devices and reagents for laboratories. The company's products include gene sequencers, human gene mutation detection kits, pathogenic detection kits, and more. Also, it offers CRO services for research applications.
- Jul 2021Series C$115.8M
- Nov 2020Series B$38M
- Jul 2019Series B$29.1M
- Jan 2019Series A$7.4M
#6
Series B · Changping District, Beijing · founded 2015 · 140 employees$165.5Mraised▾
Developer of genome editing technology for the treatment of cancer and genetic disease. The company has developed LEAPER technology, which is an in vivo oligonucleotide-based RNA single-base editing technology used for the treatment of Hurler syndrome. The company's in vitro therapy includes ET-01 for β-thalassemia major and the allogeneic CAR-T ET-02 for cancer.
- Apr 2021Series B$61.5M
- Oct 2020Series B$67M
- Sep 2019Series A$11.5M
- Feb 2019Series A$10.5M
#7
Series B · Haidian, Beijing · founded 2016 · 13 employees$16.6Mraised▾
Provider of infrared spectroscopy brain function imaging solutions. The system is meant for neuroscience, psychology, physiology, human function, rehabilitation, and mental illness. The solutions are portable and come with data analysis software for the analysis of results.
- Oct 2023Series B$13.7M
- Jun 2022Series A—
- Jul 2021Series A—
- Sep 2020Series A$1.5M
#8
Series C · Chaoyang, Beijing · founded 2018$78.7Mraised▾
Juventas is a developer of immune cell therapy drugs for the treatment of blood cancers. The drugs developed are HY001 (acute lymphoblastic leukemia), HY002 (acute myeloid leukemia) and HY015 (multiple myeloma).
- Oct 2021Series C$64.2M
- Jul 2019Series A$14.5M
#9
Series D · Beijing, Beijing · founded 2012 · 2000 employees$113Mraised▾
CapitalBio Tech is a developer of microfluidic chips for the treatment of multiple diseases. It has developed smart devices that help in microarray solutions like array production, array reaction, sample preparation, data analysis, array scanning, data management, and others. It also provides various products such as respiratory pathogens nucleic acid detection kit, gene mutations detection kit, aminoglycoside-induced deafness gene mutations detection kit, and many more.
- Jun 2020Series D$113M
#10
Series B · Beijing, Beijing · founded 2016 · 70 employees$47.3Mraised▾
Developer of cell therapies to treat cancer. The company has developed a T cell engineering platform that enables antigen-specific TCR cloning, T cell genetic engineering, and TCR repertoire analysis. They are planning to initiate clinical trials for the treatment of HPV-related cervical and head/neck cancers.
- Feb 2022Series B$47.3M
- Apr 2019Series A—
- Dec 2018Series A—
- 2017Series A—
#11
Series B · Haidian, Beijing · founded 2016$31.3Mraised▾
Beijing Haosi Biotechnology offers services in analytical testing using mass spectroscopy. The company has developed clinical mass spectrometry screening products, including Alzheimer's disease, cardiovascular disease, and urinary diseases. It also helps in the screening of genetic metabolic diseases, drug concentration testing, metabolite testing (amino acids, fatty acids, bile acids), steroid testing, and more
- Jun 2021Series B$31.3M
- Dec 2020Series B—
#12
Series B · Beijing, Beijing · founded 2003 · 102 employees$21.2Mraised▾
Provider of reagents and kits for molecular biology research. The product line includes gene expression vectors, protein expression detection and quantification, protein-protein and protein-ligand interactions, antibodies, reporter kits, and assays.
- Nov 2020Series B$21.2M
- Jul 2017Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Beijing is moving
A read on the academic research around Bioinformatics in Beijing — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 762 papers.
Beijing's institutions—led by Beijing Proteome Research Center and Beijing Tian Tan Hospital—research single-cell transcriptomics and cancer immunotherapy biomarkers with an optimistic tone (mean stance 0.52, breakthroughs dominating).
- Beijing University of Chinese Medicine82
- Beijing Proteome Research Center35
- Beijing Tian Tan Hospital31
- Beijing University of Chemical Technology28
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine28
- Gene2→24
- Genome3→17
- Identification (biology)2→14
- Metagenomics1→9
- Phenotype1→6
- Mechanism (biology)1→16
- Identification (biology)1→9
- Function (biology)1→8
- microRNA1→8
- Drug delivery1→4
- Disease13
- Immune system12
- Translational research8
- Cancer8
- Biomarker7
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.